A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102-Reference-Cited by-同舟云学术

A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102

Published:2019-05-15 Issue:10 Volume:58 Page:1405-1410
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Yokoi Takashi¹²,Minami Seigo³,Shiroyama Takayuki⁴,Koba Taro³⁵,Torii Yoshitaro¹,Sugimoto Hiroyuki¹,Niki Maiko¹,Mori Masahide⁶,Morimura Osamu⁵,Hirashima Tomonori⁴,Komuta Kiyoshi³,Kijima Takashi²⁵

Affiliation:

1. Department of Thoracic Oncology, Kansai Medical University Hospital, Japan

2. Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan

3. Department of Respiratory Medicine, Osaka Police Hospital, Japan

4. Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan

5. Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Japan

6. Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/10/58_1172-18/_pdf

Reference11 articles.

1. 1. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.

2. 2. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.

3. 3. Okamoto I, Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 10: 290-294, 2009.

4. 4. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japanoncology group study. J Clin Oncol 28: 5240-5246, 2010.

5. 5. Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan OncologyGroup LETS study. Ann Oncol 24: 1326-1331, 2013.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung;Lung Cancer;2021-12

2. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study;World Journal of Surgical Oncology;2021-08-06

3. Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer;Medicine;2021-02-26

4. Phase I trial of nedaplatin and S‑1 in patients with advanced squamous cell lung cancer;Molecular and Clinical Oncology;2020-10-23

5. Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma;Journal of Chemotherapy;2020-10-12